| Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 400 (10349), 359-368, 2022 | 226 | 2022 |
| High-dose interleukin2–a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome S Chow, V Galvis, M Pillai, R Leach, E Keene, A Spencer-Shaw, ... Journal for immunotherapy of cancer 4, 1-12, 2016 | 23 | 2016 |
| Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open … O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet 401 (10387), 1499-1507, 2023 | 18 | 2023 |
| Clinical practice outcomes of patients treated with pazopanib for metastatic renal cell cancer (mRCC)-6 year experience at a referral centre in Manchester, UK V Galvis, S Chow, FC Thistlethwaite, D Lawrence, RE Hawkins EUROPEAN JOURNAL OF CANCER 49, S663-S663, 2013 | 16 | 2013 |
| Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, J Abbas, K Abbas, M Abbas, S Abbasi, ... The Lancet Diabetes & Endocrinology 11 (12), 905-914, 2023 | 11 | 2023 |
| Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised … SN Faust, R Haynes, CE Jones, N Staplin, E Whittaker, T Jaki, E Juszczak, ... The Lancet Child & Adolescent Health 8 (3), 190-200, 2024 | 6 | 2024 |
| Selecting patients for high-dose interleukin-2 on the basis of tumour histology R Hawkins, V Galvis, A Shablak, A Spencer-Shaw, F Thistlethwaite, ... Annals of Oncology 23, ix267, 2012 | 6 | 2012 |
| 10 year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC). S Chow, MR Pillai, V Galvis, R Leach, E Keene, K Chan, A Spencer-Shaw, ... Journal of Clinical Oncology 34 (15_suppl), e16085-e16085, 2016 | 3 | 2016 |
| Evaluating the place of interleukin-2 in the management of metastatic renal cell cancer (mRCC) in the era of targeted therapy M Evans, S Chow, V Galvis, R Leach, E Keene, A Spencer-Shaw, ... Annals of Oncology 25, vi1, 2014 | 2 | 2014 |
| Genitourinary tumors, non-prostate A Ravaud, C Barrios, Ö Anak, D Pelov, A Louveau, B Alekseev, T MH, ... Annals of Oncology-English Edition 23 (9), ix258, 2012 | 2 | 2012 |
| Outcomes of patients with metastatic renal cell cancer treated with sunitinib in clinical practice at a reference cancer centre in Manchester, United Kingdom. V Galvis, D Lawrence, M Howell, F Thistlethwaite, RE Hawkins Journal of Clinical Oncology 31 (6_suppl), 477-477, 2013 | 1 | 2013 |
| Treatment of metastatic renal cancer with high-dose interleukin-2 after targeted therapy. RE Hawkins, V Galvis, J Shanks, N Dalal, F Thistlethwaite, ... Journal of Clinical Oncology 30 (5_suppl), 439-439, 2012 | 1 | 2012 |
| High dose Interleukin 2 (HD IL2) as 1st line treatment in metastatic renal cell carcinoma (mRCC): A 10-year single centre experience. S Chow, V Galvis, M Pillai, R Leach, E Keene, A Spencer-Shaw, L Tom, ... Journal of Clinical Oncology 34 (15_suppl), 4555-4555, 2016 | | 2016 |
| High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc)-a 10 year single-site experience and outcome of prospective pathology-based patient … S Chow, M Evans, V Galvis, R Leach, E Keene, K Chan, A Spencer-Shaw, ... Journal for ImmunoTherapy of Cancer 2, 1-2, 2014 | | 2014 |
| High-Dose Interleukin-2 (Hd Il2) Armed with Pathology-Based Selection Criteria: a Real Option in Treatment of Metastatic Renal Cell Carcinoma (Mrcc) After Targeted Therapy S Chow, V Galvis, M Evans, K Chan, A Spencer-Shaw, R Leach, ... Annals of Oncology 25, iv294, 2014 | | 2014 |
| Comparative effectiveness of pazopanib and sunitinib in renal cell carcinoma using real world data. DT Steinke, D Lawrence, G Saunders, F Angus, DM Ashcroft, V Galvis 29th International Conference on Pharmacoepidemiology and Therapeutic Risk …, 2013 | | 2013 |
| P044 Sequential everolimus in metastatic Renal Cell Carcinoma (mRCC): A single-institution experience in clinical practice K Chan, S Chow, V Galvis, D Lawrence, A Spencer-Shaw, ... European Urology Supplements 6 (12), 146, 2013 | | 2013 |
